Notably, under identical experimental conditions, the expression of the NK cell-activating ligand MICA was markedly upregulated, suggesting an intriguing potential for combinatorial therapeutic approaches in conjunction with other anti-MM agents. This evidence concerns the gene MICA and Miyoshi myopathy.